Hims & Hers Health, Inc. is anticipated to report earnings per share (EPS) of $0.11 for the current quarter, reflecting a substantial 120% increase from the same period last year. Revenue is projected ...

ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” first quarter ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Cedar Grove Capital Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Telehealth platform Hims & Hers Health, Inc. (HIMS), which connects consumers to healthcare professionals, is at a crossroads ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...

Jefferies analyst Glen Santangelo raised the firm’s price target on Hims & Hers to $25 from $21 and keeps a Hold rating on the shares. A ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...

Shares of Hims & Hers Health ( HIMS 12.82%) surged on Tuesday, closing the session up 5.25% after having been up by as much ...